Page 3 - Simon Travis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Vedolizumab more effectively induced remission compared with placebo in patients with chronic pouchitis following ileal pouch-anal anastomosis for ulcerative colitis, according to research in The New England Journal of Medicine.“Idiopathic inflammation of the pouch — referred to as pouchitis — is the most common long-term complication of ileal pouch-anal anastomosis (IPAA); it

The incidence of mPDAI-defined remission at week 14 was 31% in the vedolizumab group, compared to 10% in the placebo group.

The medication also showed favorable endoscopic and histologic responses.

12% of people with ulcerative colitis need surgery to have their colon removed (colectomy). Most of those have an ileo-anal pouch surgically constructed from their small bowel, which means that they don't have to live with a stoma bag.

FRIDAY, March 31, 2023 (HealthDay News) -- For patients with chronic pouchitis after undergoing restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) for ulcerative colitis, treatment with vedolizumab is more effective